Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States.
adverse event
bedaquiline
multidrug-resistant tuberculosis
outcome
treatment
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
30
06
2019
accepted:
17
09
2019
pubmed:
27
9
2019
medline:
28
4
2021
entrez:
27
9
2019
Statut:
ppublish
Résumé
In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events. Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non-US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26-116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%). Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.
Sections du résumé
BACKGROUND
In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series.
METHODS
Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events.
RESULTS
Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non-US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26-116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%).
CONCLUSIONS
Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.
Identifiants
pubmed: 31556947
pii: 5574390
doi: 10.1093/cid/ciz914
pmc: PMC7350275
mid: NIHMS1599321
doi:
Substances chimiques
Antitubercular Agents
0
Diarylquinolines
0
bedaquiline
78846I289Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1010-1016Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Références
Eur Respir J. 2013 Jul;42(1):169-179
pubmed: 23060633
Lung India. 2018 Jan-Feb;35(1):78-81
pubmed: 29319042
Eur Respir J. 2017 May 21;49(5):
pubmed: 28529205
Drugs. 2014 Jun;74(9):1041-5
pubmed: 24923253
Lancet. 2014 Apr 5;383(9924):1230-9
pubmed: 24439237
Lancet. 2018 Sep 8;392(10150):821-834
pubmed: 30215381
Emerg Infect Dis. 2014 May;20(5):812-21
pubmed: 24751166
Public Health Action. 2018 Mar 21;8(1):7-13
pubmed: 29581937
N Engl J Med. 2009 Jun 4;360(23):2397-405
pubmed: 19494215
Eur Respir J. 2016 Feb;47(2):394-402
pubmed: 26828052
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331043
J Clin Tuberc Other Mycobact Dis. 2019 Jan 27;15:100090
pubmed: 31720417
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331046
Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6
pubmed: 22391540
JAMA. 2008 Nov 12;300(18):2153-60
pubmed: 19001626
Lancet Respir Med. 2018 Sep;6(9):699-706
pubmed: 30001994
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751411
MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12
pubmed: 24157696